Overview

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Status:
Not yet recruiting

Trial end date:
2030-10-01

Target enrollment:

Participant gender:

Summary

Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.

Phase:

Phase 2

Details

Lead Sponsor:

Davendra Sohal

Treatments:

Durvalumab
Tremelimumab